Navigation Links
WAVi Co. Announces Collaborative Agreement with SomaLogic, Inc.
Date:8/1/2011

BOULDER, Colo., Aug. 1, 2011 /PRNewswire-iReach/ -- WAVi Co. announced today it has entered into a collaboration agreement with SomaLogic, Inc. Under the agreement, WAVi will apply its unique bioinformatics expertise to SomaLogic's proprietary proteomic assays for an undisclosed fee. In addition, the companies agree to work together to plan two clinical research studies in dementia that will combine WAVi's EEG (electroencephalogram)-based biomarkers and SomaLogic's blood-based protein biomarkers.

"This collaboration with SomaLogic validates both our world-class bioinformatics capabilities as well as the potential of WAVi's brain assessment platform – a platform designed as a point of care, rapid screening device providing an objective and accurate measurement to aid in the early detection and diagnosis of cognitive ailments and other neurological disorders," said Stephen K. Onody, President and CEO of WAVi. "Our mission is pre-symptomatic detection leading to early diagnosis enabling timely treatmentof cognitive ailments. Dementia costs the U.S. $183 billion per year and it is estimated that 1 in 8 people will develop Alzheimer's.  The WAVi system is designed to assist physicians to ensure patients are treated or referred to specialist care when need exists."

Larry Gold, PhD, SomaLogic Chief Executive Officer added "We are delighted to begin this collaboration with WAVi, and believe that our unique contributions to our joint work will speed the early detection and diagnosis not just of dementia but many different human diseases, offering the possibility for earlier and more effective therapeutic interventions."

About WAVi Co.

WAVi Co. (www.ewavi.com) is a privately held, medical technology company developing the first simple to use, low-cost, EEG brain assessment platform suitable for mass screening.  The WAVi device is designed to determine deviation from norm utilizing a normative database and/or self-comparison to aid in early detection and diagnosis of cognitive ailments and other neurological disorders.

CAUTION: THE WAVi SYSTEM IS AN INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE.

About SomaLogic

SomaLogic, Inc., is a privately held biomarker discovery and clinical proteomics company based in Boulder, Colorado. The company's mission is to use its proprietary Slow-Offrate Modified Aptamer ("SOMAmer") technology to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate target validation, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.

Media Contact: Stephen Onody WAVi Co., 720-542-3855, steveo@ewavi.com


'/>"/>
SOURCE WAVi Co.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
2. International Isotopes Inc. Announces Successful International Standards Certification for Manufacture of Its Nuclear Medicine Products and Devices
3. Biocept, Inc. Announces Availability of Its New Breast Cancer Test, OncoCEE-BRâ„¢ Utilizing Circulating Tumor Cells (CTCs)
4. TriLink BioTechnologies, Inc. Announces License Agreement with Lucigen Corporation
5. Verenium Announces Debt Repurchase
6. Life Technologies Announces Second Quarter 2011 Results
7. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
8. Dyadic International Announces Date of Second Quarter 2011 Financial Results Release and Conference Call
9. MiMedx Group Announces Second Quarter 2011 Results
10. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
11. ADVENTRX Announces Appointment of Senior Vice President, Commercial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
Breaking Biology News(10 mins):